# Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)

Source: https://onco.cc/trials/nct01124253/  
OnCo record `nct01124253` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Shanghai Jiao Tong University School of Medicine, completed.

## Summary

Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) is a phase 3 interventional study registered as NCT01124253 by Shanghai Jiao Tong University School of Medicine, with 250 participants recorded, started 2007-07 and reaching its primary completion in 2009-10. Interventions recorded: recombinant human endostatin. Conditions recorded: Non-small Cell Lung Cancer.

Linked to the drug Recombinant human endostatin because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01124253
- Phase: 3
- Setting: Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
- Sponsor: Shanghai Jiao Tong University School of Medicine
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT01124253: https://clinicaltrials.gov/study/NCT01124253

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Recombinant human endostatin](https://onco.cc/drugs/recombinant-human-endostatin/)

---
JSON: https://onco.cc/api/v1/entities/nct01124253.json